ASS1 and colorectal carcinoma: Further experiments combining ASS1 knockdown (ShASS1) with EVO treatment confirmed that in contrast to the EVO-only cohort, the group receiving combined treatment showed a marked reduction in arginine levels, a lower rate of EdU positivity, and diminished colony formation in CRC cells.